Filing Flows › Connect Biopharma Holdings (CNTB) › Q2 2025
Connect Biopharma Holdings (CNTB) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
Connect Biopharma Holdings (CNTB) reported revenue of $48K for the second quarter 2025 (Q2 2025), -100% from a year earlier.
Connect Biopharma Holdings, Q2 2025: revenue $48K (-100% year over year), net loss $12.9M, operating cash flow −$12.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $48K | — | -100% |
| Operating profit | −$13.4M | — | — |
| Net earnings | −$12.9M | — | — |
| Operating cash flow | −$12.6M | — | — |
What changed
Revenue was $48K in Q2 2025, down 100% year over year.
Operating costs exceeded revenue by $13.4M, an operating margin of -27966.7%. Total costs grew 29% against a revenue fall of 100%. The fastest-growing cost line was Research & development (+64%). The quarter ended with a net loss of $12.9M.
Operating cash flow was −$12.6M. Non-cash charges added back $171K of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items used $814K. Capital expenditures of $303K exceeded it, leaving free cash flow of −$12.9M.
Questions
What was Connect Biopharma Holdings' revenue in the second quarter 2025?
Connect Biopharma Holdings (CNTB) reported revenue of $48K for the second quarter 2025 (Q2 2025), -100% from a year earlier.